These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31425641)

  • 1. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
    Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
    J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study.
    Bramuzzo M; Arrigo S; Romano C; Filardi MC; Lionetti P; Agrusti A; Dipasquale V; Paci M; Zuin G; Aloi M; Strisciuglio C; Miele E; Pastore M; Martelossi S; Alvisi P;
    United European Gastroenterol J; 2019 Jul; 7(6):759-766. PubMed ID: 31316780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.
    Friesen CA; Calabro C; Christenson K; Carpenter E; Welchert E; Daniel JF; Haslag S; Roberts CC
    J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):265-9. PubMed ID: 15319627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of clinical characteristics and drug treatment of inflammatory bowel disease in children: a single center study].
    Zhang R; Zhong XM; Gong YZ; Ma X; Zhu D; Ning HJ; Wang FP; Zou JZ; Zhang YL
    Zhonghua Er Ke Za Zhi; 2020 Jul; 58(7):570-575. PubMed ID: 32605341
    [No Abstract]   [Full Text] [Related]  

  • 5. Infliximab in inflammatory bowel disease. Is premedication necessary?
    Nuñez F P; Quera R; Simian D; Flores L; Figueroa C; Ibañez P; Kronberg U; Lubascher J; Pizarro G
    Gastroenterol Hepatol; 2021 May; 44(5):321-329. PubMed ID: 33386199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher Prevalence of Monogenic Cause Among Very Early Onset Inflammatory Bowel Disease in Children: Experience From a Tertiary Care Center From Northern India.
    Poddar U; Aggarwal A; Jayalakshmi K; Sarma MS; Srivastava A; Rawat A; Yachha SK
    Inflamm Bowel Dis; 2023 Oct; 29(10):1572-1578. PubMed ID: 36594920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
    Qazi T; Shah B; El-Dib M; Farraye FA
    Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R
    Inflamm Bowel Dis; 2024 Sep; 30(9):1529-1535. PubMed ID: 37819840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
    Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic and genotypic characterization of inflammatory bowel disease in children under six years of age in China.
    Fang YH; Luo YY; Yu JD; Lou JG; Chen J
    World J Gastroenterol; 2018 Mar; 24(9):1035-1045. PubMed ID: 29531467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease.
    Kelsen JR; Conrad MA; Dawany N; Patel T; Shraim R; Merz A; Maurer K; Sullivan KE; Devoto M
    Inflamm Bowel Dis; 2020 May; 26(6):909-918. PubMed ID: 31560377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
    Jacobstein DA; Markowitz JE; Kirschner BS; Ferry G; Cohen SA; Gold BD; Winter HS; Heyman MB; Baldassano RN
    Inflamm Bowel Dis; 2005 May; 11(5):442-6. PubMed ID: 15867583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
    J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study.
    Fiorino G; Cortes PN; Ellul P; Felice C; Karatzas P; Silva M; Lakatos PL; Bossa F; Ungar B; Sebastian S; Furfaro F; Karmiris K; Katsanos KH; Muscat M; Christodoulou DK; Maconi G; Kopylov U; Magro F; Mantzaris GJ; Armuzzi A; Boscà-Watts MM; Ben-Horin S; Bonovas S; Danese S
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1426-1432.e1. PubMed ID: 27317850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
    Pearce CB; Lawrance IC
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.